Menard Financial Group LLC Purchases 12,305 Shares of Pfizer Inc. (NYSE:PFE)

Key Points

• Menard Financial Group LLC increased its stake in Pfizer Inc. by 3,155.1% in the first quarter, now owning 12,695 shares valued at approximately $322,000.
• Pfizer reported a quarterly earnings per share (EPS) of $0.92, surpassing the consensus estimate of $0.67, although revenue decreased by 7.8% year-over-year.
• The company announced a quarterly dividend of $0.43 per share, yielding 7.22%, with a dividend payout ratio currently at 124.64%.

Menard Financial Group LLC grew its holdings in Pfizer Inc. (NYSE:PFE - Free Report) by 3,155.1% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 12,695 shares of the biopharmaceutical company's stock after purchasing an additional 12,305 shares during the period. Menard Financial Group LLC's holdings in Pfizer were worth $322,000 as of its most recent SEC filing.

A number of other large investors also recently made changes to their positions in the business. Massachusetts Financial Services Co. MA boosted its position in Pfizer by 7.5% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 76,502,238 shares of the biopharmaceutical company's stock worth $2,029,604,000 after purchasing an additional 5,350,381 shares during the period. Northern Trust Corp boosted its position in shares of Pfizer by 7.7% in the fourth quarter. Northern Trust Corp now owns 58,382,560 shares of the biopharmaceutical company's stock valued at $1,548,889,000 after acquiring an additional 4,167,222 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in shares of Pfizer by 3.5% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 39,402,619 shares of the biopharmaceutical company's stock valued at $1,045,351,000 after acquiring an additional 1,333,740 shares during the period. Invesco Ltd. boosted its position in shares of Pfizer by 9.6% in the fourth quarter. Invesco Ltd. now owns 29,458,139 shares of the biopharmaceutical company's stock valued at $781,524,000 after acquiring an additional 2,579,455 shares during the period. Finally, Pacer Advisors Inc. boosted its position in shares of Pfizer by 856.8% in the first quarter. Pacer Advisors Inc. now owns 20,053,828 shares of the biopharmaceutical company's stock valued at $508,164,000 after acquiring an additional 17,957,928 shares during the period. Institutional investors and hedge funds own 68.36% of the company's stock.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on PFE shares. Redburn Atlantic reduced their price objective on Pfizer from $29.00 to $27.00 and set a "neutral" rating for the company in a research report on Wednesday, April 30th. TD Cowen reduced their price objective on Pfizer from $32.00 to $28.00 and set a "hold" rating for the company in a research report on Tuesday, April 22nd. UBS Group increased their price objective on Pfizer from $24.00 to $25.00 and gave the company a "neutral" rating in a research report on Wednesday, April 30th. Citigroup upped their target price on Pfizer from $23.00 to $25.00 and gave the company a "neutral" rating in a research note on Wednesday, April 30th. Finally, Berenberg Bank cut their target price on Pfizer from $28.00 to $25.00 and set a "hold" rating for the company in a research note on Thursday, May 29th. One investment analyst has rated the stock with a sell rating, eleven have issued a hold rating, six have given a buy rating and three have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Pfizer presently has a consensus rating of "Moderate Buy" and a consensus price target of $28.28.

Pfizer Price Performance

Shares of NYSE:PFE traded up $0.20 during midday trading on Friday, reaching $23.49. The company's stock had a trading volume of 51,287,529 shares, compared to its average volume of 38,018,180. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $31.32. The company has a market capitalization of $133.55 billion, a P/E ratio of 17.02, a P/E/G ratio of 0.84 and a beta of 0.52. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.26 and a quick ratio of 0.96. The business's fifty day simple moving average is $24.36 and its 200-day simple moving average is $24.60.

Pfizer (NYSE:PFE - Get Free Report) last announced its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, beating analysts' consensus estimates of $0.67 by $0.25. Pfizer had a return on equity of 20.33% and a net margin of 12.62%. The company had revenue of $13.72 billion during the quarter, compared to analyst estimates of $14.43 billion. During the same period last year, the company posted $0.82 earnings per share. The firm's quarterly revenue was down 7.8% compared to the same quarter last year. As a group, equities research analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 2nd. Investors of record on Friday, July 25th will be issued a $0.43 dividend. The ex-dividend date is Friday, July 25th. This represents a $1.72 annualized dividend and a yield of 7.3%. Pfizer's dividend payout ratio (DPR) is currently 124.64%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.